Phase 4
Completed N=359
Clinical and Economic Implications of Genetic Testing for Warfarin Management
Blood Coagulation Disorders
Source: ClinicalTrials.gov NCT00964353 ↗
Enrolled (actual)
359
Serious AEs
2.2%
Results posted
Nov 2019
Primary outcomePrimary: Inpatient Length of Stay — 6.8; 7.2 days
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to explore how knowing genes that individuals inherit from their parents can make warfarin dosing more safe and effective. This study is being done to determine whether providing doctors with data on the genes their patients inherited and warfarin dosing recommendations based on those genes affects the costs and outcomes of care and after hospitalization for patients from different ethnic/racial backgrounds, and how physicians use this information in decision making.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Inpatient Length of Stay |
6.8; 7.2 | — |
| SECONDARY Supratherapeutic Dosing |
2.2; 2.2 | — |
Eligibility Criteria
Inclusion Criteria
- warfarin-naive patients
- ages 18 and older
- are undergoing inpatient anticoagulation initiation with warfarin for diagnoses that necessitate anticoagulation
Exclusion Criteria
- patients who are not warfarin-naive
- 17 years of age or younger
Data sourced from ClinicalTrials.gov (NCT00964353). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.